Prior Authorization for Medication: How to Get Approved (2026)

Prior authorization for medication is one of the biggest sources of treatment delay in U.S. healthcare. Physicians report spending an average of 14 hours per week on PA paperwork. Patients face an average delay of 6.4 days to access approved medications—and 33% of PA denials are overturned on appeal, meaning a third of initial denials were wrong. Here is how to navigate the process and get your medication approved.

1. Which drugs typically require prior authorization

Not every prescription requires PA. Insurers and pharmacy benefit managers (PBMs) apply PA requirements selectively to control costs for high-utilization or high-cost drugs. The most common categories:

Your specific plan’s formulary determines which drugs require PA. Find this information in your plan’s drug list (formulary), available on your insurer’s website. Look for “PA” or “ST” (step therapy) next to specific drugs.

2. Step therapy: the “fail first” requirement

Step therapy requires you to try a less expensive drug before your insurer will cover the one your doctor prescribed. For example, before covering a biologic like Humira for rheumatoid arthritis, a plan may require you to try and fail methotrexate and at least one other conventional DMARD.

You can request a step therapy exception if any of these apply:

• You previously tried the required step therapy drug and it was ineffective or caused an adverse reaction—document this with medical records
• The required drug is contraindicated for your condition (e.g., a kidney disease patient cannot safely take NSAIDs required in the step protocol)
• You are already clinically stable on the prescribed medication and switching would cause harm
• The required drug is not available due to a shortage
• A clinician determines that trying the required drug would cause irreversible harm

As of 2026, more than 30 states have enacted step therapy exception laws that require insurers to have a clear exception process and respond within defined timelines. Check whether your state has such a law and cite it explicitly in your exception request.

3. How to get your doctor to submit a PA request

The PA process begins with your prescribing doctor, not with you. Here is how to move it forward quickly:

1. Ask your doctor at the appointment. Before leaving, confirm whether the prescription will require PA. Many EMR systems flag this automatically at the point of prescribing.
2. Make sure the PA request is submitted promptly. PA is submitted by your doctor’s office, not by you. Ask specifically who in the office handles PA submissions and confirm it will be submitted within 24 hours.
3. Provide complete documentation proactively. The most common cause of PA delay is missing documentation. Relevant documentation includes: current diagnosis codes, supporting lab results or imaging, a list of prior medications tried and their outcomes, and the specific clinical indication for the requested drug.
4. Ask your doctor to call the insurer’s medical director directly (peer-to-peer review) if the PA is delayed or denied. This single step resolves a large proportion of denials before formal appeals are necessary.
5. Check the status. Call your insurance company 2 business days after submission to confirm the PA request was received and is being processed. Get a reference number.

4. PA timelines and the new 2026 CMS rules

PA decision timelines vary by plan type and urgency:

• Urgent / expedited requests: 24–72 hours (federal minimum for marketplace and Medicare Advantage plans)
• Non-urgent (standard) requests: 3–10 business days for most commercial plans; 72 hours for Medicare Advantage under 2026 CMS rules
• Appeals after denial: 30–60 days for standard appeal; 72 hours for expedited

New CMS Prior Authorization rules effective 2026: CMS finalized a rule in 2024 requiring Medicare Advantage plans and Medicaid managed care plans to:

• Respond to urgent PA requests within 24 hours (reduced from 72 hours)
• Respond to standard PA requests within 72 hours (reduced from 7 days)
• Share PA data through standardized FHIR APIs, making it easier for patients and providers to track PA status electronically
• Provide specific reasons for PA denials and cite the clinical criteria used
• Limit PA requirements to evidence-based clinical criteria only

These rules apply to Medicare Advantage plans, Medicaid managed care plans, and marketplace QHP issuers. Commercial employer-sponsored plans are not covered by this rule but many states have enacted similar requirements.

5. What to do if PA is denied

A PA denial is not final. Here are your options in order of how quickly they typically resolve:

1. Peer-to-peer review (fastest). Your doctor calls the insurer’s medical director. This is a physician-to-physician conversation about your specific case. Many denials reverse at this stage within 1–2 days. Ask your doctor to request this immediately.
2. Formal appeal. Submit a written appeal with a letter of medical necessity, clinical guidelines supporting the drug’s use for your condition, and documentation of any failed alternatives. A BillKarma analysis found 33% of PA denials are overturned on appeal.
3. Exception request. If denied for step therapy reasons, submit a step therapy exception request with documentation of why the required alternatives are inappropriate for you.
4. External review. If your internal appeal is denied, request external review by an independent organization. The IRO’s decision is binding on the insurer.
5. Manufacturer patient assistance programs (PAPs). Most major pharmaceutical manufacturers offer programs that provide medications free or at dramatically reduced cost to patients who meet income criteria or who are fighting coverage denials. Apply at the manufacturer’s website or through NeedyMeds.org or RxAssist.org while your appeal is pending.
6. State insurance commissioner complaint. If the insurer violated required timelines or failed to provide adequate denial reasons, file a complaint with your state’s insurance commissioner.

6. Gold carding: exemptions for high-approval prescribers

Gold carding exempts a prescriber from prior authorization requirements for specific drug classes based on their historical approval rate. If a doctor’s PA requests for a drug class are approved 90%+ of the time, requiring PA for that physician wastes everyone’s time.

States with gold carding laws (as of 2026):

• Texas — requires health plans to exempt physicians with a 90%+ approval rate from PA requirements for specific services or drugs
• Louisiana — 90% approval rate threshold; applies to Medicaid managed care and commercial plans
• Arkansas, West Virginia, Virginia — enacted gold carding laws requiring insurer compliance
• CMS — developing a gold carding framework for Medicare Advantage plans; expected finalization in 2026

If your prescribing doctor frequently prescribes a drug that requires PA, ask their office whether they have applied for or qualify for gold card status with your specific insurer. If not, encourage them to—it removes the PA burden for all of their patients on that drug.

7. Cost of going without PA vs. paying out of pocket

Sometimes patients consider skipping the PA process and paying out of pocket. This almost never makes financial sense for specialty medications, but for some lower-cost drugs it may be worth comparing:

• GoodRx / discount pharmacies: For generic medications and some brands, GoodRx or Cost Plus Drugs prices may be lower than your plan’s cost-sharing even with coverage. Check before filing a PA.
• Specialty drugs: Almost never cheaper out of pocket. Biologics that cost $20,000–$100,000+/year have $0 list price programs through manufacturers for qualifying patients, but these are separate from PA processes.
• GLP-1 medications: Without insurance coverage, Wegovy lists at approximately $1,350/month; Ozempic at $1,000/month. Manufacturer savings cards may reduce this to $25/month for eligible commercially insured patients during disputes.
• The real cost of waiting: For conditions like cancer, autoimmune disease, or severe mental illness, treatment delay has clinical consequences. Pursue all appeal options aggressively and simultaneously.

Frequently asked questions

Sources

• CMS: Advancing Interoperability and Improving Prior Authorization Processes Final Rule (2024)
• AMA: 2025 AMA Prior Authorization Physician Survey
• KFF: Prior Authorization in Medicare Advantage (2024)
• National Academy for State Health Policy: State Prior Authorization and Step Therapy Laws (2025)
• CMS: Medicare Advantage Prior Authorization Compliance Data (2025)